OM
EPZM

Opaleye Management’s Epizyme, Inc EPZM Stock Holding History

Opaleye Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,384,200
Closed -$34.1M – 54
2019
Q4 		$34.1M Buy
1,384,200
+19,200
+1% +$285K 6.68% 1
2019
Q3 		$14.1M Hold
1,365,000
– – 5.09% 3
2019
Q2 		$17.1M Hold
1,365,000
– – 5.22% 4
2019
Q1 		$16.9M Buy
1,365,000
+240,000
+21% +$2.68M 4.68% 3
2018
Q4 		$6.93M Buy
1,125,000
+925,000
+463% +$7.06M 2.59% 9
2018
Q3 		$2.12M Sell
200,000
-75,000
-27% -$856K 0.54% 37
2018
Q2 		$3.73M Buy
275,000
+205,000
+293% +$3.19M 0.96% 31
2018
Q1 		$1.24M Buy
+70,000
New +$1.18M 0.36% 34
2014
Q2 		– Sell
-115,500
Closed -$2.63M – 34
2014
Q1 		$2.63M Buy
+115,500
New +$3.5M 1.94% 16

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Opaleye Management's EPZM Position: Q1 2020 in Review

Opaleye Management sold out of Epizyme, Inc (EPZM) in Q1 2020, closing a stake of 1,384,200 shares — an estimated $34.1M sold.

Opaleye Management first reported a position in EPZM in Q1 2014 and held it in 9 quarters. The position peaked at $34.1M in Q4 2019. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

  • Opaleye Management reported no remaining Epizyme, Inc position as of Q1 2020 after selling out during the quarter.
  • Opaleye Management sold 1,384,200 Epizyme, Inc shares in Q1 2020, an estimated $34.1M.
  • Opaleye Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 9 quarters.
  • Opaleye Management's Epizyme, Inc position peaked at $34.1M in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.